Results were similar to those in the original analysis; a unit increase in CASP-19 intercept was associated with a 2% (p < .001) reduction in arthritis risk via the direct pathway and 0.003% reduction in arthritis risk via the indirect pathway (via CRP intercept) (p = .004). This evidence concerns the gene CRP and arthritic joint disease.